intranasal glutathione alzheimers drug delivery for treatment of Alzheimer's disease | Drug Delivery and Translational Research Intranasal Nanoemulsions for the Management
Description
However, in contrast to untransformed human T-cells, in which SFN treatment led to a decrease of GSH, the GSH level in Jurkat T-leukemia cells showed a significant increase after 1 day of SFN treatment (Figure 4D)
This is true for all other animals, from birds to pigs, from frogs to humans
Injectable and nasal spray delivery bypasses digestion entirely, delivering glutathione directly at therapeutic concentrations
Our previous studies showed that hirsutinolides inhibit the expression of G6PD and TrxR1 in human glioblastoma models [23]
